Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale

Clinical Biochemistry

Volumn 47, Issue 13-14, 2014, Pages 1333-1336

  Mauté, Carole ^a   Nibourel, Olivier ^b   Réa, Delphine ^a   Coiteux, Valérie ^b   Grardel, Nathalie ^b   Preudhomme, Claude ^b   Cayuela, Jean Michel ^a,c  

^a SAINT LOUIS HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

BCR ABL1; Chronic myeloid leukemia; International scale; Real time quantitative PCR; Standardization

Indexed keywords

BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; MESSENGER RNA;

CALIBRATION; CHRONIC MYELOID LEUKEMIA; GENETICS; HUMAN; STANDARD;

CALIBRATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REFERENCE STANDARDS; RNA, MESSENGER;

EID: 84929133951     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.05.067     Document Type: Article

References (12)

1. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27(35):6041-6051.
2. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122(6):872-884.
3. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108(1):28-37.
4. Branford S., Fletcher L., Cross N.C., Muller M.C., Hochhaus A., Kim D.W., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008, 112(8):3330-3338.
5. Muller M.C., Cross N.C., Erben P., Schenk T., Hanfstein B., Ernst T., et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009, 23(11):1957-1963.
6. White H.E., Matejtschuk P., Rigsby P., Gabert J., Lin F., Wang L., et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010, 116(22):e111-e117.
7. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17(12):2318-2357.
8. Winn-Deen E.S., Helton B., Van Atta R., Wong W., Peralta J., Wang J., et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem 2007, 53(9):1593-1600.
9. Foroni L., Wilson G., Gerrard G., Mason J., Grimwade D., White H.E., et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 2011, 153(2):179-190.
10. Cayuela J.M., Macintyre E., Darlington M., Abdelali R.B., Fund X., Villarese P., et al. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?. Haematologica 2011, 96(5):664-671.
11. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
12. Bland J.M., Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8(2):135-160.